Transcatheter aortic valve replacement (TAVR) has become the standard of care for patients with severe aortic valve stenosis in the last decade, particularly in patients who are at high surgical risk. Clinical trials have shown that TAVR is more appropriate than medicinal treatment for such high-surgical-risk patients. With the advances in TAVR technology, more emphasis is given to the development of valves, selecting appropriate patients, assessing risks, and other procedural concerns which will ensure safe and effective performance of TAVR valves. Join this session organized by Docplexus , where Dr.
G. Sengottuvelu will discuss the “Significance of TAVR: India Standpoint”, on 23rd June 2021, 6 PM onwards. To get insights from the expert, be part of this session!
